Disease/Infection News

RSS

Family planning drive launched during conference in Uganda

Agence France-Presse examines a new U.S.-backed "12 million dollar family planning drive launched" Wednesday during a three-day conference on family planning in Kampala, Uganda. The project aims to "improve access to contraceptives for women in six African nations [including Uganda, Ethiopia, Nigeria, Senegal, Tanzania and Kenya] as well as Indonesia and Pakistan," the news service writes (Simon, 11/18).

19 Nov 2009

Also in Global Health News: HIV/AIDS grant giving; Africa's water resources; sex workers in Malawi

HIV/AIDS program grants made by U.S.-based foundations totaled $618 billion in 2008, an 11 percent increase from the previous year, according to a new report by Funders Concerned About AIDS, the Chronicle of Philanthropy reports. The Bill & Melinda Gates Foundation accounted for the majority of the grants, and when it was "excluded, foundation giving [for HIV/AIDS] actually declined 3 percent compared to 2007."

19 Nov 2009

Adamas Pharmaceuticals expands its Phase 2 TCAD therapy study for influenza A

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.

19 Nov 2009

SinoFresh Nasal Spray effective against 'swine flu' in animal study

SinoFresh Healthcare Products, Inc. announced today the successful results of its initial pilot animal study testing the efficacy of the SinoFresh Nasal Spray product when used on animals infected with the H1N1 virus. The study data suggests that treatment with SinoFresh allowed the infected animals to recover more rapidly from H1N1 infection than did untreated animals. In addition, pre-treatment with SinoFresh Nasal Spray decreased the severity and/or incidence of infection.

19 Nov 2009

First comprehensive, international baseline evidence about pandemics published

Public health officials walking a tightrope between massive demand for vaccines and intense public scrutiny of side effects now have a new standard for evaluating the safety of their vaccination programs.

19 Nov 2009

Exaggerated responses of immune system explain elders’ susceptibility to viral infections

Researchers at Yale School of Medicine have found that exaggerated responses of the immune system explain why the elderly succumb to viral infections more readily than younger people. Published in the November 19 Cell Host & Microbe, the study bucks the general belief that declining immune responses are to blame for susceptibility to viral infections.

19 Nov 2009

Early diagnosis and treatment is crucial for pulmonary hypertension, a rare but deadly disease

We often hear about the perils of high blood pressure, but many Canadians are unaware that high blood pressure in the lungs - known as pulmonary hypertension (PH) - can also have fatal consequences. This month, the Pulmonary Hypertension Association of Canada hopes to raise awareness about PH - a rare but serious disease that can strike at any time and has no regard for race, age or gender.

19 Nov 2009

NPSF supports obligatory flu vaccination for healthcare workers

The National Patient Safety Foundation recognizes vaccine-preventable diseases as a matter of patient safety and supports mandatory influenza vaccination of health care workers to protect the health of patients, health care workers, and the community.

19 Nov 2009

UNGASS monitoring system provides the overall progress in the global response to HIV

Although much work remains to be done, a United Nations global reporting system on HIV/AIDS has already yielded an "unequaled wealth of data" on progress toward meeting UN targets for responding to the global HIV epidemic. An update on the development of the UN General Assembly Special Session on HIV/AIDS (UNGASS) global reporting system appears in a special supplement to JAIDS: Journal of Acquired Immune Deficiency Syndromes.

19 Nov 2009

Why avian flu virus has not caused a pandemic?

Bird flu viruses would have to make at least two simultaneous genetic mutations before they could be transmitted readily from human to human, according to research published today in PLoS ONE.

19 Nov 2009

Malaria experts urge Congress to increase funding for malaria programs

While efforts to control and eliminate malaria have made great strides during the past five years, the looming specter of drug resistance heightens the importance of continued research and development for new tools to assure continued success, according to malaria scientists and public health experts appearing today on Capitol Hill.

19 Nov 2009

Pfizer and DNDi to battle against HAT, VL and Chagas disease

Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world.

19 Nov 2009

Chronic hepatitis B seems to progress faster in men, report scientists

Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women. Their study has been published online in ACS' Journal of Proteome Research, a monthly publication.

19 Nov 2009

WHO to launch yellow fever vaccination campaign in West Africa

The WHO on Tuesday announced it would lead a week-long, multi-country vaccination campaign in Africa next week to protect those "deemed at highest risk from yellow fever," Reuters reports.

19 Nov 2009

Opinions: Fighting TB; currency transaction tax

Though tuberculosis "is one of the world's leading killers … few citizens, scientists and policymakers are demanding more attention to TB research, treatment and prevention. … It's time to bring TB research into the 21st century," Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, writes in an MSNBC opinion piece.

19 Nov 2009

GAVI Alliance drives down pentavalent vaccine costs, data shows

The "co-ordinated buying policy" of the GAVI Alliance has driven down "[t]he price of a vaccine that helps babies fight off killer diseases," according to data released by the group, Reuters reports. In 2010, the price of pentavalent vaccine, which protects against Hib (Haemophilus influenzae type b), diphtheria, whooping cough, tetanus and hepatitis B, will fall "below $3.0 - a drop of almost $0.50 cents per dose on the 2009 price," according to the news services.

19 Nov 2009

mdBriefCase to provide online education course on H1N1 virus in pregnant women

mdBriefCase Inc., in collaboration with the Public Health Agency of Canada (PHAC) and the Society of Obstetrics and Gynecology of Canada (SOGC), is pleased to provide a new online education course on the H1N1 virus in pregnant women.

18 Nov 2009

U.S. health officials testify before Senate Committee about H1N1 vaccine campaign

U.S. health officials defended their handling of the country's H1N1 (swine flu) vaccine campaign Tuesday "against criticism that their plan to protect Americans was confusing and over-optimistic," Reuters reports (Fox, 11/17).

18 Nov 2009

Also in Global Health news: Sleeping sickness; aid for Philippines; U.S., China in Africa; polio eradication in Afghanistan; Ethiopia famine

Lancet Infectious Diseases Newsdesk examines how despite evidence that a new therapy to treat sleeping sickness, called nifurtimox—eflornithine (NECT) is a step forward in treating the disease, it has yet to be implemented by countries "13 months after data from a successful trial was presented." The main issue at hand - "nifurtimox is not registered for use in sleeping sickness," the journal writes. The article also examines other factors complicating the implementation of the therapy (Morris, 12/09).

18 Nov 2009

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

CEL-SCI Corporation, a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the start of the Company's first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins).

18 Nov 2009